Effect of aldose reductase inhibition on nerve conduction and morphometry in diabetic neuropathy

Douglas A. Greene, Joseph C. Arezzo, M. B. Brown

Research output: Contribution to journalArticle

219 Citations (Scopus)

Abstract

Objective: To determine whether the aldose reductase inhibitor (ARI) zenarestat improves nerve conduction velocity (NCV) and nerve morphology in diabetic peripheral polyneuropathy (DPN). Methods: A 52-week, randomized, placebo-controlled, double-blinded, multiple-dose, clinical trial with the ARI zenarestat was conducted in patients with mild to moderate DPN. NCV was measured at baseline and study end. Contralateral sural nerve biopsies were obtained at 6 weeks and at the study's end for nerve sorbitol measurement and computer-assisted light morphometry to determine myelinated nerve fiber density (number of fibers/mm2 cross-sectional area) in serial bilateral sural nerve biopsies. Results: Dose-dependent increments in sural nerve zenarestat level and sorbitol suppression were accompanied by significant improvement in NCV. In a secondary analysis, zenarestat doses producing >80% sorbitol suppression were associated with a significant increase in the density of small-diameter (<5 μm) sural nerve myelinated fibers. Conclusions: Aldose reductase pathway inhibition improves NCV slowing and small myelinated nerve fiber loss in DPN in humans, but >80% suppression of nerve sorbitol content is required. Thus, even low residual levels of aldose reductase activity may be neurotoxic in diabetes, and potent ARIs such as zenarestat may be required to stop or reverse progression of DPN.

Original languageEnglish (US)
Pages (from-to)580-591
Number of pages12
JournalNeurology
Volume53
Issue number3
StatePublished - Aug 11 1999

Fingerprint

Aldehyde Reductase
Diabetic Neuropathies
Neural Conduction
Sorbitol
Sural Nerve
Biopsy
Myelinated Nerve Fibers
Placebos
FR 74366
Clinical Trials
Light

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Effect of aldose reductase inhibition on nerve conduction and morphometry in diabetic neuropathy. / Greene, Douglas A.; Arezzo, Joseph C.; Brown, M. B.

In: Neurology, Vol. 53, No. 3, 11.08.1999, p. 580-591.

Research output: Contribution to journalArticle

@article{2e378509f0c44f63ac2c5f1e564e7a64,
title = "Effect of aldose reductase inhibition on nerve conduction and morphometry in diabetic neuropathy",
abstract = "Objective: To determine whether the aldose reductase inhibitor (ARI) zenarestat improves nerve conduction velocity (NCV) and nerve morphology in diabetic peripheral polyneuropathy (DPN). Methods: A 52-week, randomized, placebo-controlled, double-blinded, multiple-dose, clinical trial with the ARI zenarestat was conducted in patients with mild to moderate DPN. NCV was measured at baseline and study end. Contralateral sural nerve biopsies were obtained at 6 weeks and at the study's end for nerve sorbitol measurement and computer-assisted light morphometry to determine myelinated nerve fiber density (number of fibers/mm2 cross-sectional area) in serial bilateral sural nerve biopsies. Results: Dose-dependent increments in sural nerve zenarestat level and sorbitol suppression were accompanied by significant improvement in NCV. In a secondary analysis, zenarestat doses producing >80{\%} sorbitol suppression were associated with a significant increase in the density of small-diameter (<5 μm) sural nerve myelinated fibers. Conclusions: Aldose reductase pathway inhibition improves NCV slowing and small myelinated nerve fiber loss in DPN in humans, but >80{\%} suppression of nerve sorbitol content is required. Thus, even low residual levels of aldose reductase activity may be neurotoxic in diabetes, and potent ARIs such as zenarestat may be required to stop or reverse progression of DPN.",
author = "Greene, {Douglas A.} and Arezzo, {Joseph C.} and Brown, {M. B.}",
year = "1999",
month = "8",
day = "11",
language = "English (US)",
volume = "53",
pages = "580--591",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Effect of aldose reductase inhibition on nerve conduction and morphometry in diabetic neuropathy

AU - Greene, Douglas A.

AU - Arezzo, Joseph C.

AU - Brown, M. B.

PY - 1999/8/11

Y1 - 1999/8/11

N2 - Objective: To determine whether the aldose reductase inhibitor (ARI) zenarestat improves nerve conduction velocity (NCV) and nerve morphology in diabetic peripheral polyneuropathy (DPN). Methods: A 52-week, randomized, placebo-controlled, double-blinded, multiple-dose, clinical trial with the ARI zenarestat was conducted in patients with mild to moderate DPN. NCV was measured at baseline and study end. Contralateral sural nerve biopsies were obtained at 6 weeks and at the study's end for nerve sorbitol measurement and computer-assisted light morphometry to determine myelinated nerve fiber density (number of fibers/mm2 cross-sectional area) in serial bilateral sural nerve biopsies. Results: Dose-dependent increments in sural nerve zenarestat level and sorbitol suppression were accompanied by significant improvement in NCV. In a secondary analysis, zenarestat doses producing >80% sorbitol suppression were associated with a significant increase in the density of small-diameter (<5 μm) sural nerve myelinated fibers. Conclusions: Aldose reductase pathway inhibition improves NCV slowing and small myelinated nerve fiber loss in DPN in humans, but >80% suppression of nerve sorbitol content is required. Thus, even low residual levels of aldose reductase activity may be neurotoxic in diabetes, and potent ARIs such as zenarestat may be required to stop or reverse progression of DPN.

AB - Objective: To determine whether the aldose reductase inhibitor (ARI) zenarestat improves nerve conduction velocity (NCV) and nerve morphology in diabetic peripheral polyneuropathy (DPN). Methods: A 52-week, randomized, placebo-controlled, double-blinded, multiple-dose, clinical trial with the ARI zenarestat was conducted in patients with mild to moderate DPN. NCV was measured at baseline and study end. Contralateral sural nerve biopsies were obtained at 6 weeks and at the study's end for nerve sorbitol measurement and computer-assisted light morphometry to determine myelinated nerve fiber density (number of fibers/mm2 cross-sectional area) in serial bilateral sural nerve biopsies. Results: Dose-dependent increments in sural nerve zenarestat level and sorbitol suppression were accompanied by significant improvement in NCV. In a secondary analysis, zenarestat doses producing >80% sorbitol suppression were associated with a significant increase in the density of small-diameter (<5 μm) sural nerve myelinated fibers. Conclusions: Aldose reductase pathway inhibition improves NCV slowing and small myelinated nerve fiber loss in DPN in humans, but >80% suppression of nerve sorbitol content is required. Thus, even low residual levels of aldose reductase activity may be neurotoxic in diabetes, and potent ARIs such as zenarestat may be required to stop or reverse progression of DPN.

UR - http://www.scopus.com/inward/record.url?scp=0033546655&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033546655&partnerID=8YFLogxK

M3 - Article

C2 - 10449124

AN - SCOPUS:0033546655

VL - 53

SP - 580

EP - 591

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 3

ER -